Literature DB >> 15331239

Smoking, nicotine and Parkinson's disease.

Maryka Quik1.   

Abstract

Epidemiological studies show that smoking is associated with a lower incidence of Parkinson's disease (PD). This finding is important because it could provide clues about therapeutic strategies for protection against this debilitating movement disorder. Smoke contains numerous chemicals that could be responsible for the apparent protective effect. Here, a role for nicotine is considered, because this chemical stimulates brain dopaminergic systems and provides some symptomatic benefit in PD. Nicotine also has a neuroprotective action. Putative factors and signaling pathways involved in the actions of nicotine are discussed. An understanding of the molecular basis for the reduced occurrence of PD in tobacco users is crucial for the development of intervention strategies to reduce or halt disease progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15331239     DOI: 10.1016/j.tins.2004.06.008

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  83 in total

Review 1.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

2.  Parkinson's disease research in a prospective cohort in China.

Authors:  Honglei Chen; Ding Ding; Jian Wang; Qianhua Zhao; Haijiao Meng; Honglan Li; Yu-Tang Gao; Xiao-Ou Shu; Caroline M Tanner; Zhen Hong; Gong Yang
Journal:  Parkinsonism Relat Disord       Date:  2015-08-20       Impact factor: 4.891

3.  Antiparkinsonian effects of aqueous methanolic extract of Hyoscyamus niger seeds result from its monoamine oxidase inhibitory and hydroxyl radical scavenging potency.

Authors:  T Sengupta; J Vinayagam; N Nagashayana; B Gowda; P Jaisankar; K P Mohanakumar
Journal:  Neurochem Res       Date:  2010-10-23       Impact factor: 3.996

4.  First-principles calculation of pKa for cocaine, nicotine, neurotransmitters, and anilines in aqueous solution.

Authors:  Haiting Lu; Xi Chen; Chang-Guo Zhan
Journal:  J Phys Chem B       Date:  2007-08-11       Impact factor: 2.991

Review 5.  Neuronal nicotinic receptors as novel targets for inflammation and neuroprotection: mechanistic considerations and clinical relevance.

Authors:  Merouane Bencherif
Journal:  Acta Pharmacol Sin       Date:  2009-06       Impact factor: 6.150

Review 6.  Mysterious alpha6-containing nAChRs: function, pharmacology, and pathophysiology.

Authors:  Ke-chun Yang; Guo-zhang Jin; Jie Wu
Journal:  Acta Pharmacol Sin       Date:  2009-06       Impact factor: 6.150

7.  Enhancement of nicotinic receptors alleviates cytotoxicity in neurological disease models.

Authors:  Jun Kawamata; Syuuichirou Suzuki; Shun Shimohama
Journal:  Ther Adv Chronic Dis       Date:  2011-05       Impact factor: 5.091

8.  Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease.

Authors:  Eliseu Felippe dos Santos; Estela Natacha Brandt Busanello; Anelise Miglioranza; Angela Zanatta; Alethea Gatto Barchak; Carmen Regla Vargas; Jonas Saute; Charles Rosa; Maria Júlia Carrion; Daiane Camargo; André Dalbem; Jaderson Costa da Costa; Sandro René Pinto de Sousa Miguel; Carlos Roberto de Mello Rieder; Moacir Wajner
Journal:  Metab Brain Dis       Date:  2009-03-18       Impact factor: 3.584

Review 9.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

Review 10.  Nicotine and inflammatory neurological disorders.

Authors:  Wen-Hua Piao; Denise Campagnolo; Carlos Dayao; Ronald J Lukas; Jie Wu; Fu-Dong Shi
Journal:  Acta Pharmacol Sin       Date:  2009-05-18       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.